Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552125 | 0.84 | HCRTR1 (0.48) | HCRTR1HCRTR2MLYCDHSP90AA1HSP90AB1 | |
| SCHEMBL3553495 | 0.83 | HCRTR1 (0.47) | HCRTR1HCRTR2MLYCDHSP90AA1HSP90AB1 | |
| SCHEMBL3555397 | 0.82 | KMT2A (0.54) | HSP90AA1HSP90AB1MEN1KMT2AKDM4E | |
| SCHEMBL3560278 | 0.80 | HCRTR1 (0.45) | HCRTR1HCRTR2MLYCDHSP90AA1HSP90AB1 | |
| SCHEMBL3550257 | 0.80 | HCRTR1 (0.63) | HCRTR1HCRTR2TSHR | |
| SCHEMBL4465339 | 0.78 | MLYCD (0.43) | MLYCDHSP90AA1HSP90AB1PDE4BTSHR | |
| SCHEMBL3559186 | 0.76 | HCRTR1 (0.44) | HCRTR1HCRTR2MLYCDHSP90AA1HSP90AB1 | |
| SCHEMBL4469757 | 0.76 | HSP90AA1 (0.45) | MLYCDHSP90AA1HSP90AB1KDM4ETSHR | |
| SCHEMBL23773234 | 0.74 | SIGMAR1 (0.38) | CNR2TSHRSIGMAR1ALDH1A1 | |
| SCHEMBL3555893 | 0.73 | CYP3A4 (0.49) | HSP90AA1HSP90AB1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1675859-A1 | MODULATORS OF SEROTONIN RECEPTORS | Bristol-Myers Squibb Company (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | HCRTR1 33/4885HCRTR2 42/4885MLYCD 1202/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | HCRTR1 34/4885HCRTR2 42/4885MLYCD 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.